Cardiac samples

Working in collaboration with the University of Kentucky Center for Transplant and Organ Failure and the Gill Heart Institute, the Campbell lab manages a collection of cardiac tissue isolated from organ donors and patients undergoing surgeries.

Since 2008, we have procured ~5000 samples from different regions of ~250 human hearts. Most of the samples are flash-frozen and subsequently stored in the vapor phase of liquid nitrogen but we have also performed experiments using living myocytes and electrically isolated trabecualae. All of the samples are linked to medical records.

Collaborations

Our IRB protocol allows us to share deidentified samples that have been acquired since November 2013 with scientific collaborators.

All requests to initiate new collaborations must be approved by the IRB committee (or equivalent) of the requesting institution. The requesting institution also needs to complete a standard University of Kentucky Materials Transfer Agreement before we are allowed to release specimens.

The requesting instution pays shipping costs. We also ask that any members of our biobanking program who have made significant contributions to the final study are included as authors on any resulting publications.

For more information, email biobank@campbellmusclelab.org.

Summary data and additional information about our program


Blair, Cheavar A.; Haynes, Premi; Campbell, Stuart G.; Chung, Charles; Mitov, Mihail I.; Dennis, Donna; Bonnell, Mark R.; Hoopes, Charles W.; Guglin, Maya; and Campbell, Kenneth S. (2016) "A Protocol for Collecting Human Cardiac Tissue for Research," The VAD Journal: Vol. 2 , Article 12. DOI: http://dx.doi.org/10.13023/VAD.2016.12


Thank you

The Campbell lab would like to thank everybody who helps with this program. It's a complex difficult initiative and we rely on many tens of people at the University of Kentucky who go above and beyond to support our research.

We also want to specifically recognize the patients, donors, and families of donors, who chose to support our research. We are trying to pay you back by accelerating research that will lead to improved treatment options for patients who have heart failure.

Ċ
Ken Campbell,
Feb 17, 2017, 11:39 AM